Combination of Interferon-β and the Angiotensin-Converting Enzyme Inhibitor, Perindopril, Attenuates Murine Hepatocellular Carcinoma Development and Angiogenesis

Clinical Cancer Research

Volumn 9, Issue 16, 2003, Pages 6038-6045

  Noguchi, Ryuichi ^a   Yoshiji, Hitoshi ^a   Kuriyama, Shigeki ^b   Yoshii, Junichi ^a   Ikenaka, Yasuhide ^a   Yanase, Koji ^a   Namisaki, Tadashi ^a   Kitade, Mitsuteru ^a   Yamazaki, Masaharu ^a   Mitoro, Akira ^a   Tsujinoue, Hirohisa ^a   Imazu, Hiroo ^a   Masaki, Tsutomu ^b   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA INTERFERON; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PERINDOPRIL;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATTENUATION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG POTENCY; ENDOTHELIUM CELL; ENZYME INHIBITION; IN VITRO STUDY; INTERFERON PRODUCTION; LIVER CELL CARCINOMA; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VASCULAR ENDOTHELIUM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; HUMANS; INTERFERON-BETA; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; PERINDOPRIL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0347995046     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Carmeliet, P., and Jain, R. K. Angiogenesis in cancer and other diseases. Nature (Lond.), 407: 249-257, 2000.
2. Kerbel, R. S. Tumor angiogenesis: past, present and the near future. Carcinogenesis (Lond.), 21: 505-515, 2000.
3. Saaristo, A., Karpanen, T., and Alitalo, K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene, 19: 6122-6129, 2000.
4. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med., 6: 389-395, 2000.
5. Kerbel, R. S. A cancer therapy resistant to resistance. Nature (Lond.), 390: 335-336, 1997.
6. Kerbel, R. S. Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J. Clin. Oncol., 19: 45S-51S, 2001.
7. Lever, A. F., Hole, D. J., Gillis, C. R., McCallum, I. R., McInnes, G. T., MacKinnon, P. L., Meredith, P. A., Murray, L. S., Reid, J. L., and Robertson, J. W. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet, 352: 179-184, 1998.
8. Matsusaka, T., and Ichikawa, I. Biological functions of angiotensin and its receptors. Annu. Rev. Physiol., 59: 395-412, 1997.
9. Hori, K., Saito, S., Takahashi, H., Sato, H., Maeda, H., and Sato, Y. Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride. Jpn. J. Cancer Res., 91: 261-269, 2000.
10. Le Noble, F. A., Hekking, J. W., Van Straaten, H. W., Slaaf, D. W., and Struyker Boudier, H. A. Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. Eur. Pharmacol., 195: 305-306, 1991.
11. Kardum, D., Huskic, J., Fabijanic, D., Banic, M., Buljevac, M., Kujundzic, M., and Loncar, B. Activity of serum angiotensin-converting enzyme as a tumour marker of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol., 11: 1209-1213, 1999.
12. Yoshiji, H., Kuriyama, S., Kawata, M., Yoshii, J., Ikenaka, Y., Noguchi, R., Nakatani, T., Tsujinoue, H., and Fukui, H. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin. Cancer Res., 7: 1073-1078, 2001.
13. Baron, S., and Dianzani, F. The interferons: a biological system with therapeutic potential in viral infections. Antiviral Res., 24: 97-110, 1994.
14. Hertzog, P. J., Hwang, S. Y., and Kola, I. Role of interferons in the regulation of cell proliferation, differentiation, and development. Mol. Reprod. Dev., 39: 226-232, 1994.
15. Dong, Z., Greene, G., Pettaway, C., Dinney, C. P., Eue, I., Lu, W., Bucana, C. D., Balbay, M. D., Bielenberg, D., and Fidler, I. J. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-β. Cancer Res., 59: 872-879, 1999.
16. Ribatti, D., Vacca, A., Iurlaro, M., Ria, R., Roncali, L., and Dammacco, F. Human recombinant interferon alpha-2a inhibits angiogenesis of chick area vasculosa in shell-less culture. Int. J. Microcirc. Clin. Exp., 16: 165-169, 1996.
17. Hong, Y. K., Chung, D. S., Joe, Y. A., Yang, Y. J., Kim, K. M., Park, Y. S., Yung, W. K., and Kang, J. K. Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-β treatment at early stage of tumor development. Clin. Cancer Res., 6: 3354-3360, 2000.
18. Izawa, J. I., Sweeney, P., Perrotte, P., Kedar, D., Dong, Z., Slaton, J. W., Karashima, T., Inoue, K., Benedict, W. F., and Dinney, C. P. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-β gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin. Cancer Res., 8: 1258-1270, 2002.
19. Cao, G., Su, J., Lu, W., Zhang, F., Zhao, G., Marteralli, D., and Dong, Z. Adenovirus-mediated interferon-β gene therapy suppresses growth and metastasis of human prostate cancer in nude mice. Cancer Gene Ther., 8: 497-505, 2001.
20. Wang, L., Tang, Z. Y., Qin, L. X., Wu, X. F., Sun, H. C., Xue, Q., and Ye, S. L. High-dose and long-term therapy with interferon-β inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology, 32: 43-48, 2000.
21. Ikeda, K., Arase, Y., Saitoh, S., Kobayashi, M., Suzuki, Y., Suzuki, F., Tsubota, A., Chayama, K., Murashima, N., and Kumada, H. Interferon β prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology, 32: 228-232, 2000.
22. Nishiguchi, S., Kuroki, T., Nakatani, S., Morimoto, H., Takeda, T., Nakajima, S., Shiomi, S., Seki, S., Kobayashi, K., and Otani, S. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet, 346: 1051-1055, 1995.
23. Yoshiji, H., Kuriyama, S., Ways, D. K., Yoshii, J., Miyamoto, Y., Kawata, M., Ikenaka, Y., Tsujinoue, H., Nakatani, T., Shibuya, M., and Fukui, H. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res., 59: 4413-4418, 1999.
24. Yoshiji, H., Kuriyama, S., Hicklin, D. J., Huber, J., Yoshii, J., Miyamoto, Y., Kawata, M., Ikenaka, Y., Nakatani, T., Tsujinoue, H., and Fukui, H. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology, 30: 1179-1186, 1999.
25. Yoshii, J., Yoshiji, H., Kuriyama, S., Ikenaka, Y., Noguchi, R., Okuda, H., Tsujinoue, H., Nakatani, T., Kishida, H., Nakae, D., Gomez, D. E., Der Lorenzo, M. S., Tejera, A. M., and Fukui, H. The copperchelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. Int. J. Cancer, 94: 768-773, 2001.
26. Shibuya, M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct. Funct., 26: 25-35, 2001.
27. Yoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Noguchi, R., Hicklin, D. J., Huber, J., Nakatani, T., Tsujinoue, H., Yanase, K., Imazu, H., and Fukui, H. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology, 35: 834-842, 2002.
28. Befeler, A. S., and Di Bisceglie, A. M. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology, 122: 1609-1619, 2002.
29. Schafer, D. F., and Sorrell, M. F. Hepatocellular carcinoma. Lancet, 353: 1253-1257, 1999.
30. Suzuki, K., Hayashi, N., Miyamoto, Y., Yamamoto, M., Ohkawa, K., Ito, Y., Sasaki, Y., Yamaguchi, Y., Nakase, H., Noda, K., Enomoto, N., Arai, K., Yamada, Y., Yoshihara, H., Tujimura, T., Kawano, K., Yoshikawa, K., and Kamada, T. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res., 56: 3004-3009, 1996.
31. Yamaguchi, R., Yano, H., Iemura, A., Ogasawara, S., Haramaki, M., and Kojiro, M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology, 28: 68-77, 1998.
32. Yoshiji, H., Kuriyama, S., Yoshii, J., Yamazaki, M., Kikukawa, M., Tsujinoue, H., Nakatani, T., and Fukui, H. Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology, 28: 1489-1496, 1998.
33. Ferrara, N. VEGF: an update on biological and therapeutic aspects. Curr. Opin. Biotechnol., 11: 617-624, 2000.
34. Williams, B., Baker, A. Q., Gallacher, B., and Lodwick, D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension, 25: 913-917, 1995.
35. Helmy, A., Jalan, R., Newby, D. E., Hayes, P. C., and Webb, D. J. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology, 118: 565-572, 2000.
36. Arroyo, V., Bosch, J., Mauri, M., Ribera, F., Navarro-Lopez, F., and Rodes, J. Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur. J. Clin. Invest., 11: 221-229, 1981.
37. Yoshiji, H., Yoshii, J., Ikenaka, Y., Noguchi, R., Yanase, K., Tsujinoue, H., Imazu, H., and Fukui, H. Suppression of the reninangiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int. J. Oncol., 20: 1227-1231, 2002.
38. Slaton, J. W., Perrotte, P., Inoue, K., Dinney, C. P., and Fidler, I. J. Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res., 5: 2726-2734, 1999.
39. Oliveira, I. C., Sciavolino, P. J., Lee, T. H., and Vilcek, J. Downregulation of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proc. Natl. Acad. Sci. USA, 89: 9049-9053, 1992.
40. Dinney, C. P., Bielenberg, D. R., Perrotte, P., Reich, R., Eve, B. Y., Bucana, C. D., and Fidler, I. J. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res., 58: 808-814, 1998.
41. Bolling, B., Fandrey, J., Frosch, P. J., and Acker, H. VEGF production, cell proliferation and apoptosis of human IGR 1 melanoma cells under nIFN-α/β and rIFN-γ treatment. Exp. Dermatol., 9: 327-335, 2000.
42. da Silva, A. J., Brickelmaier, M., Majeau, G. R., Lukashin, A. V., Peyman, J., Whitty, A., and Hochman, P. S. Comparison of gene expression patterns induced by treatment of human umbilical vein endothelial cells with IFN-α2b vs. IFN-β1a: understanding the functional relationship between distinct type I interferons that act through a common receptor. J. Interferon Cytokine Res., 22: 173-188, 2002.
43. Scappaticci, F. A., Smith, R., Pathak, A., Schloss, D., Lum, B., Cao, Y., Johnson, F., Engleman, E. G., and Nolan, G. P. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol. Ther., 3: 186-196, 2001.
44. Minischetti, M., Vacca, A., Ribatti, D., Iurlaro, M., Ria, R., Pellegrino, A., Gasparini, G., and Dammacco, A. F. TNP-470 and recombinant human interferon-α2a inhibit angiogenesis synergistically. Br. J. Haematol., 109: 829-837, 2000.
45. Thiollet, M., Funck-Brentano, C., Grange, J. D., Midavaine, M., Resplandy, G., and Jaillon, P. The pharmacokinetics of perindopril in patients with liver cirrhosis. Br. J. Clin. Pharmacol., 33: 326-328, 1992.
46. Yoshiji, H., Kuriyama, S., and Fukui, H. Perindopril: possible use in cancer therapy. Anticancer Drugs, 13: 221-228, 2002.